Physician profile
Saima Abbas
NPI 1023272010
$830.40
in general payments reported to CMS, 2019-2025
9 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $199 · 2024: $286 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $302.88 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $274.54 | 2022-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $76.04 | 2022-2025 | Nuzyra |
| Shionogi INC | $51.47 | 2022-2024 | Fetroja |
| Abbvie INC. | $39.41 | 2025 | |
| Viiv Healthcare Company | $25.68 | 2025 | Dovato |
| Philips North America LLC | $25.26 | 2024 | (Ak6) Vest Therapy |
| Ferring Pharmaceuticals INC. | $18.04 | 2024 | Rebyota |
| Gilead Sciences, INC. | $17.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.